Semaglutide vial 7-12 bundle Options
The trial attained each its primary endpoints, with semaglutide 2.4 mg demonstrating statistically significant and exceptional advancements in liver fibrosis with no worsening of steatohepatitis, together with resolution of steatohepatitis with no worsening of liver fibrosis in those with MASH in comparison with placebo.1These highlights usually do